Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06932302 · ClinicalTrials.gov registry record · NA

At-Home Neuromodulation for Female Sexual Dysfunction

A NA study of Female Sexual Dysfunction, sponsored by University of Michigan.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06932302 is a NA study of Female Sexual Dysfunction that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 24 participants, below the 84-participant average among 4 other Female Sexual Dysfunction trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06932302, a NA study of Female Sexual Dysfunction, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can improve FSD arousal symptoms in premenopausal and postmenopausal women. Some subjects will use a smart vibrator for comparison to DGS.

Conditions Studied

Interventions

  • DEVICE Electrical Stimulation
  • DEVICE Smart vibrator

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-10-15
Est. Completion 2027-11
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT06932302

The ClinicalTrials.gov registry entry for NCT06932302 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 4 other Female Sexual Dysfunction trials with a reported enrollment target (71% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Female Sexual Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Electrical Stimulation is the first listed.

NCT06932302 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06932302 about?

NCT06932302 is a clinical study titled "At-Home Neuromodulation for Female Sexual Dysfunction". This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can impr...

What is the current status of trial NCT06932302?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-10-15. Estimated completion is 2027-11.

What conditions does trial NCT06932302 study?

This clinical trial studies the following conditions: Female Sexual Dysfunction.

What interventions are being tested in trial NCT06932302?

The interventions under investigation include: Electrical Stimulation (DEVICE), Smart vibrator (DEVICE).

Who is sponsoring clinical trial NCT06932302?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06932302 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Female Sexual Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.